The latest price target for Royalty Pharma (NASDAQ:RPRX) was reported by Goldman Sachs on August 14, 2024. The analyst firm set a price target for $51.00 expecting RPRX to rise to within 12 months (a possible 80.15% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Royalty Pharma (NASDAQ:RPRX) was provided by Goldman Sachs, and Royalty Pharma maintained their buy rating.

The last upgrade for Royalty Pharma PLC happened on April 14, 2022 when JP Morgan raised their price target to $50. JP Morgan previously had a neutral for Royalty Pharma PLC.

The last downgrade for Royalty Pharma PLC happened on June 3, 2024 when UBS changed their price target from N/A to $28 for Royalty Pharma PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $50.00 to $51.00. The current price Royalty Pharma (RPRX) is trading at is $28.31, which is out of the analyst’s predicted range.